2 year study of secukinumab (AIN457) treatment in patients with active Psoriatic Arthritis

Update Il y a 4 ans
Reference: EUCTR2011-000276-34

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To demonstrate the efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo in patients with active PsA based on the proportion of patients achieving an ACR20 response.


Inclusion criteria

  • Psoriatic Arthritis